Ourofino S.a. · BMFBOVESPA:OFSA3

Ourofino — Ourofino Saúde Animal — Q1 2026 Earnings Presentation

16 slides from Ourofino's earnings presentation

  1. Slide 1: Results Presentation | 1Q26

    Results Presentation | 1Q26 ow | G ourofino | aber uid saideanimal —«|: Cuidado

  2. Slide 2: Legal Notice

    Legal Notice This presentation contains statements about future events that are subject to risks and uncertainties. Such statements are based on the beliefs and assumptions of our Management, as well as on information currently available to the Company. Statements about future events include informa

  3. Slide 3: Highlights 1Q26

    Highlights 1Q26 NET REVENUE R$250.5 mi R$134.9 mi & 32.1% vs. 1025 & 46.9% vs. 1025 MARGIN (%) 53.9% 4 5.4 pp. vs. 1025 R$44.6 mi 17.8% 4 139.0% vs. 1025 4 7.9p.p.vs.1Q25 G ourofino | ta bem satde animal cuidado R$20.8 mi 4 902.7% vs. 1Q25

  4. Slide 4: Financial Highlights

    Financial Highlights 1Q26 R$ million 1Q25 1Q26 % Change Net Revenue - Total 189.6 250.5 32.1% Gross Profit 91.9 134.9 46.9% Gross Margin 48.5% 53.9% +5.4 p.p. Adjusted EBITDA 18.7 44.6 139.0% Adjusted EBITDA Margin 9.9% 17.8% +7.9 p.p. Adjusted Net Income 2.1 20.8 902.7% Adjusted Net Margin 1.1% 8.3

  5. Slide 5: Consolidated Results

    Consolidated Results 1Q26 + 40.4% Consolidated net revenue + 32.1% Increased by 32.1%, reaching R$250.5 million compared to 1Q25 Gross profit grew 46.9% in 1Q26, reaching R$134.9 million, with a +5.42 p.p. increase in gross R$ million margin. +5.4 p.p. in gross margin, reaching 53.9% in the quarter.

  6. Slide 6: Production Animals

    Production Animals 1Q26 + 40.6% Net revenue reached R$176.5 + 40.6% million, a growth of 40.6% compared to 1Q25. Gross profit of R$82.8 million, up 67.3% compared to 1Q25. R$ million +7.5 p.p. in gross margin, reaching 46.9% in the quarter.

  7. Slide 7: Companion Animals

    Companion Animals 1Q26 + 33.1% Net revenue reached R$45.1 + 23.4% million, a growth of 23.4% compared to 1Q25. Gross profit of R$32.0 million, up 29.6% compared to 1Q25. R$ million +3.4 p.p. in gross margin, reaching 70.9% in the quarter.

  8. Slide 8: International Operations

    International Operations 1Q26 + 52.4% Net revenue reached R$28.9 + 5.0% million, a growth of 5.0% compared to 1Q25. Gross profit of R$20.1 million, up 13.6% compared to 1Q25. R$ million +5.5 p.p. in gross margin, reaching 69.7% in the quarter.

  9. Slide 9: Adjusted SG&A

    Adjusted SG&A 1Q26 In 1Q26, they totaled R$81.9 million, a growth of 14.4% compared to 1Q25. 5.1 p.p. dilution relative to net revenue. The variations are explained by: (i) strategic investments in R$ million commercial and marketing structures, and (ii) impacts arising from collective bargaining ad

  10. Slide 10: R&D Investments

    R&D Investments 1Q26 R&D investments totaled R$19.9 million in 1Q26, of which R$18.4 million were expenses and R$1.5 million were capitalized investments. These amounts support our ongoing pipeline of research, development, and innovation projects in the income statement between periods, reflecting

  11. Slide 11: Adjusted EBITDA

    Adjusted EBITDA 1Q26 Adjusted EBITDA reached R$44.6 million in 1Q26. with a margin of 17.8%, representing an expansion of 7.9 p.p. compared to 1Q25. R$ million

  12. Slide 12: Cash Position

    Cash Position 1Q26 At the end of the quarter, R$135.1 million in operating cash flow was generated, net of interest payments on loans and income taxes (IRPJ/CSLL). In debt funding and amortization, R$30.0 million was raised, representing the remaining tranche of the new BNDES facility totaling R$60

  13. Slide 13: Capital Structure

    Capital Structure 1Q26 • Financial leverage ended the period at 0.35x LTM Adjusted EBITDA. • The average cost of debt at the end of the period was 8.47%, representing 6.28 p.p. below the Selic rate of 14.75% observed in the same period.

  14. Slide 14: Aging

    Aging 1Q26 In 1Q26, gross debt totaled R$511.8 million, an increase of 4.54% compared to LTM25, reflecting new borrowings. The gross debt profile remains well aligned with the Company’s investment profile, with 88.7% of the total in the long term, of which 41.4% matures in more than five years.

  15. Slide 15: Q&A

    Q&A G ourofino | per satide animal cuidado

  16. Slide 16: G ourofino | tabem

    4 G ourofino | tabem saude animal cuidado en acat

Ourofino Saúde Animal — Q1 2026 Earnings Presentation on 6ix